AstraZeneca: US Data Shows Vaccine Effective for All Ages
2021-03-23
LRC
TXT
大字
小字
滚动
全页
1Drug-maker AstraZeneca said Monday its vaccine provided strong protection against COVID-19.
2The two-shot vaccine also stopped hospitalizations and deaths for all age groups, including older people.
3The results came from the long-awaited study in the United States.
4In a statement, AstraZeneca said its COVID-19 vaccine was 79 percent effective at preventing COVID-19.
5The company also said its vaccine was 100 percent effective in stopping severe disease and hospitalization.
6And the vaccine worked across all ethnic groups and ages, including older people.
7The U.S. study included more than 30,000 people.
8About 20,000 were given two shots of the vaccine.
9The shots were injected four weeks apart.
10The rest received shots of inactive substance called placebos.
11AstraZeneca said its experts did not find any safety concerns.
12They also found no increased risk of unusual blood system blockages, or blood clots, that was a cause for concern in Europe.
13"These findings reconfirm previous results observed," said Ann Falsey.
14She is with the University of Rochester School of Medicine and helped lead the study.
15"It's exciting to see similar efficacy results in people over 65 for the first time," she said.
16Full information about the study, however, has not been published.
17And no outside experts have reviewed the information.
18The British-Swiss company said Monday that it will seek emergency use permission in the U.S.
19AstraZeneca's coronavirus vaccine has been approved for emergency use in more than 50 countries.
20When it was approved for emergency use in Britain last December, the shot was described as the "vaccine for the world."
21It costs much less than vaccines from Pfizer and Moderna.
22It also does not require extreme cold storage, making it easier to use in countries with limited resources.
23The AstraZeneca vaccine is a large part of the United Nations COVAX program.
24The program aims to get COVID-19 vaccines to poorer countries.
25Dr. Paul Hunter is a professor of medicine at the University of East Anglia.
26He said that more information was needed to confirm AstraZeneca's claim that the vaccine can stop severe disease and hospitalization.
27He added, however, that the results appeared hopeful.
28"This should add confidence that the vaccine is doing what it is most needed for," said Hunter, who was not connected to the study.
29Last September, AstraZeneca vaccine drug trials were temporarily suspended in both Britain and the U.S.
30The company said a woman in the study had developed inflammation in her spine.
31This led to a delay in the U.S. drug trial.
32The drug-maker was slow to report manufacturing problems last October.
33The company and its partner, Britain's University of Oxford, then reported unclear results from two different vaccine treatments in the British drug trial, which left many uncertain if it was safe and effective.
34Last week, more than 12 countries, mostly in Europe, stopped using the vaccine after reports it was linked to unusual blood clots.
35On Thursday, the European Medicines Agency said its investigation found the vaccine did not raise the risk of blood clots, other than very rare cases.
36France, Germany, Italy and other countries started using the AstraZeneca vaccine again on Friday.
37AstraZeneca said it would continue to examine the new information from the U.S. study before giving it to the FDA in the coming weeks.
38It said the study and its results will soon be published.
39I'm Susan Shand.
1Drug-maker AstraZeneca said Monday its vaccine provided strong protection against COVID-19. The two-shot vaccine also stopped hospitalizations and deaths for all age groups, including older people. 2The results came from the long-awaited study in the United States. 3In a statement, AstraZeneca said its COVID-19 vaccine was 79 percent effective at preventing COVID-19. The company also said its vaccine was 100 percent effective in stopping severe disease and hospitalization. And the vaccine worked across all ethnic groups and ages, including older people. 4The U.S. study included more than 30,000 people. About 20,000 were given two shots of the vaccine. The shots were injected four weeks apart. The rest received shots of inactive substance called placebos. 5AstraZeneca said its experts did not find any safety concerns. They also found no increased risk of unusual blood system blockages, or blood clots, that was a cause for concern in Europe. 6"These findings reconfirm previous results observed," said Ann Falsey. She is with the University of Rochester School of Medicine and helped lead the study. 7"It's exciting to see similar efficacy results in people over 65 for the first time," she said. 8Full information about the study, however, has not been published. And no outside experts have reviewed the information. 9The British-Swiss company said Monday that it will seek emergency use permission in the U.S. 10'Vaccine for the world' 11AstraZeneca's coronavirus vaccine has been approved for emergency use in more than 50 countries. 12When it was approved for emergency use in Britain last December, the shot was described as the "vaccine for the world." It costs much less than vaccines from Pfizer and Moderna. It also does not require extreme cold storage, making it easier to use in countries with limited resources. 13The AstraZeneca vaccine is a large part of the United Nations COVAX program. The program aims to get COVID-19 vaccines to poorer countries. 14Dr. Paul Hunter is a professor of medicine at the University of East Anglia. He said that more information was needed to confirm AstraZeneca's claim that the vaccine can stop severe disease and hospitalization. He added, however, that the results appeared hopeful. 15"This should add confidence that the vaccine is doing what it is most needed for," said Hunter, who was not connected to the study. 16Last September, AstraZeneca vaccine drug trials were temporarily suspended in both Britain and the U.S. The company said a woman in the study had developed inflammation in her spine. This led to a delay in the U.S. drug trial. 17The drug-maker was slow to report manufacturing problems last October. The company and its partner, Britain's University of Oxford, then reported unclear results from two different vaccine treatments in the British drug trial, which left many uncertain if it was safe and effective. 18Last week, more than 12 countries, mostly in Europe, stopped using the vaccine after reports it was linked to unusual blood clots. On Thursday, the European Medicines Agency said its investigation found the vaccine did not raise the risk of blood clots, other than very rare cases. 19France, Germany, Italy and other countries started using the AstraZeneca vaccine again on Friday. 20AstraZeneca said it would continue to examine the new information from the U.S. study before giving it to the FDA in the coming weeks. It said the study and its results will soon be published. 21I'm Susan Shand. 22The Associated Press reported this story. Susan Shand adapted it for Learning English. Hai Do was the editor. 23_______________________________________________________________ 24Words in This Story 25previous - adj. : existing or happening before the present time 26excite - v. to cause feelings of enthusiasm in (someone) 27confidence - n. a feeling or belief that you can do something well or succeed at something 28inflammation - n. a condition in which a part of your body becomes red, swollen, and painful 29We want to hear from you. Write to us in the Comments Section, and visit our Facebook page.